Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta
Hamidreza Aboulkheyr Es, Sareh Zhand, Jean Paul Thiery, et al.
Integrative Biology (2020) Vol. 12, Iss. 7, pp. 188-197
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Fanglong Wu, Jin Yang, Junjiang Liu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 459
Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Yan Zhao, Meili Shen, Liangqiang Wu, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 9
Open Access | Times Cited: 154
Targeting CAFs to overcome anticancer therapeutic resistance
Phei Er Saw, Jianing Chen, Erwei Song
Trends in cancer (2022) Vol. 8, Iss. 7, pp. 527-555
Closed Access | Times Cited: 127
Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy
Tian Zhang, Yuanbo Jia, Yang Yu, et al.
Advanced Drug Delivery Reviews (2022) Vol. 186, pp. 114319-114319
Closed Access | Times Cited: 78
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
Chiel van Geffen, Astrid Deißler, Markus Quante, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 61
Fibroblasts as Turned Agents in Cancer Progression
Robert Wieder
Cancers (2023) Vol. 15, Iss. 7, pp. 2014-2014
Open Access | Times Cited: 28
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
Samar A. Antar, Mohamed A. Saleh, Ahmed A. Al‐Karmalawy
Life Sciences (2022) Vol. 309, pp. 121048-121048
Open Access | Times Cited: 34
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Benjamin Jenkins, Josephine F. Buckingham, Christopher J. Hanley, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108231-108231
Open Access | Times Cited: 31
Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies
Yashi Xu, Wei Li, Shitong Lin, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies
Thi Kim Ngan Ngo, Cheng‐Hsiang Kuo, Ting‐Yuan Tu
Biomicrofluidics (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 14
Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis
Alexey Fayzullin, Semyon Churbanov, Natalia Ignatieva, et al.
Biomedicines (2021) Vol. 9, Iss. 8, pp. 853-853
Open Access | Times Cited: 29
Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin
Helena Branco, Júlio Oliveira, Catarina Antunes, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3631-3631
Open Access | Times Cited: 20
Despicable role of epithelial–mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens
Paras Famta, Saurabh Shah, Biswajit Dey, et al.
Cancer Pathogenesis and Therapy (2024) Vol. 3, Iss. 1, pp. 30-47
Open Access | Times Cited: 4
Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy
Di Chen, Lixia Xu, Mengjuan Xuan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 9
Open Access | Times Cited: 4
Mesenchymal stem cells induce PD‐L1 expression through the secretion of CCL5 in breast cancer cells
Hamidreza Aboulkheyr Es, Bahareh Bigdeli, Sareh Zhand, et al.
Journal of Cellular Physiology (2020) Vol. 236, Iss. 5, pp. 3918-3928
Closed Access | Times Cited: 31
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
Qin Wan, Jun Zou, Yongbiao Huang, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 29
Metallic Nanoparticle-Mediated Immune Cell Regulation and Advanced Cancer Immunotherapy
Adityanarayan Mohapatra, Padmanaban Sathiyamoorthy, In‐Kyu Park
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1867-1867
Open Access | Times Cited: 27
Targeting Cancer-Associated Fibroblasts with Pirfenidone: A Novel Approach for Cancer Therapy
Nima Rastegar‐Pouyani, Mohadeseh Haji Abdolvahab, Mohammad Amin Farzin, et al.
Tissue and Cell (2024) Vol. 91, pp. 102624-102624
Closed Access | Times Cited: 3
Immunocompetent Tumor-on-a-Chip: A Translational Tool for Drug Screening and Cancer Therapy
Anqi Liang, Tao Tao, Jiahui Chen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104716-104716
Closed Access
Unidirectional intercellular communication on a microfluidic chip
Guocheng Fang, Hongxu Lu, Hamidreza Aboulkheyr Es, et al.
Biosensors and Bioelectronics (2020) Vol. 175, pp. 112833-112833
Closed Access | Times Cited: 24
Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis
Tania Ray, Terry Ryusaki, Partha Ray
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 23
Pirfenidone Reduces Epithelial–Mesenchymal Transition and Spheroid Formation in Breast Carcinoma through Targeting Cancer-Associated Fibroblasts (CAFs)
Hamidreza Aboulkheyr Es, Thomas R. Cox, Ehsan Sarafraz-Yazdi, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5118-5118
Open Access | Times Cited: 23
Organ-on-a-chip models for development of cancer immunotherapies
M. Chernyavska, Mina Masoudnia, Thomas Valerius, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3971-3983
Open Access | Times Cited: 9
Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells
Jingjing Liu, Liming Cao, Yuanyuan Li, et al.
Human Cell (2022) Vol. 35, Iss. 6, pp. 1813-1823
Closed Access | Times Cited: 12
[Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Sheng Chen, Shuqun Zhang, Weijun Fan, et al.
PubMed (2024) Vol. 44, Iss. 2, pp. 210-216
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top